Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL572783 | 1.00 | TSHR (0.42) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperazine SCHEMBL28176112 | 1.00 | TSHR (0.42) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperazine SCHEMBL28092993 | 0.97 | TSHR (0.40) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperazine SCHEMBL4195986 | 0.87 | LMNA (0.34) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperidine SCHEMBL4297330 | 0.86 | ALDH1A1 (0.47) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperazine SCHEMBL8991321 | 0.84 | TSHR (0.42) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperazine SCHEMBL28369178 | 0.82 | TSHR (0.39) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Morpholine SCHEMBL668275 | 0.82 | MEN1 (0.50) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperazine SCHEMBL28077828 | 0.82 | TSHR (0.41) | TSHRLMNACYP3A4GABRA1GABRG2 | |
| Piperazine SCHEMBL28134580 | 0.81 | LMNA (0.43) | TSHRLMNACYP3A4GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060073163-A1 | Anti-sepsis conjugate vaccine | ENDOBIOLOGICS, INCORPORATED. | 2006-04-06 | — | — | US | claimed |
| WO-2024014512-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | 日油株式会社 | 2024-01-18 | — | — | WO | disclosed |
| WO-2023000247-A1 | APPLICATION OF α-ASARONE IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING HEMORRHAGIC STROKE | 四川大学 | 2023-01-26 | — | — | WO | disclosed |
| CN-115397340-A | Microstructure hemostat | BVW控股公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2022048197-A1 | USE OF α-ASARONE IN PREPARATION OF DRUG FOR PREVENTION OR TREATMENT OF CEREBRAL ISCHEMIC STROKE | 四川大学 | 2022-03-10 | — | — | WO | disclosed |
| EP-3761030-A1 | METHOD FOR STABILIZING PROTEIN CONTAINED IN SAMPLE AND SOLUTION FOR STABILIZING PROTEIN CONTAINED IN SAMPLE | EIKEN KAGAKU KABUSHIKI KAISHA (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407425-A1 | METHOD OF STABILIZING PROTEIN CONTAINED IN SPECIMEN AND SOLUTION FOR STABILIZING PROTEIN CONTAINED IN SPECIMEN | EIKEN KAGAKU KABUSHIKI KAISHA (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200377572-A1 | METHOD FOR STABILIZING HEMOGLOBIN-HAPTOGLOBIN COMPLEX AND A PRESERVATION SOLUTION FOR PRESERVING SPECIMENS CONTAINING HEMOGLOBIN | EIKEN KAGAKU KABUSHIKI KAISHA (JP) | 2020-12-03 | — | — | US | disclosed |
| US-10828608-B2 | Semipermeable membrane and preparation method thereof | ZHEJIANG UNIVERSITY (CN) | 2020-11-10 | — | — | US | disclosed |
| EP-3719496-A1 | METHOD FOR STABILIZING COMPLEX OF HEMOGLOBIN AND HAPTOGLOBIN AND A PRESERVATION SOLUTION FOR PRESERVING SPECIMENS CONTAINING HEMOGLOBIN | Eiken Kagaku Kabushiki Kaisha (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-5340735-A | Genetic engineering | COGNIS, INC. (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1994004562-A9 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | — | 1994-04-14 | — | — | WO | disclosed |
| WO-1994004562-A1 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1994-03-03 | — | — | WO | disclosed |
| EP-0580649-A1 | PLANT PROMOTER INVOLVED IN CONTROLLING LIPID BIOSYNTHESIS IN SEEDS | UNILEVER PLC (GB) | 1994-02-02 | — | — | EP | disclosed |
| US-5221615-A | Colorimetric, quantitative analysis using sorbitol, gelatin or ammonium sulfate buffers | Modrovich, Ivan E. (US) | 1993-06-22 | — | — | US | disclosed |
| WO-1992018634-A1 | PLANT PROMOTER INVOLVED IN CONTROLLING LIPID BIOSYNTHESIS IN SEEDS | UNILEVER PLC (GB) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992018138-A1 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0407543-A4 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | — | 1992-10-14 | — | — | EP | disclosed |
| EP-0407543-A1 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 1991-01-16 | — | — | EP | disclosed |
| WO-1990006948-A1 | MAMMALIAN GAP-43 COMPOSITIONS AND METHODS OF USE | FISHMAN MARK C (US) | 1990-06-28 | — | — | WO | disclosed |